Mark Zuckerberg backed Cellular Intelligence has acquired Novo Nordisk’s Parkinson’s cell therapy after the Danish drugmaker shut down its cell therapy unit last October. Novo Nordisk said the restructuring meant discontinuing development of the therapy. The deal signals renewed interest in the approach and could reshape the therapy’s next development and commercialization plans.
Novo Nordisk is relaunching a diabetes tablet in the United States under the Ozempic name, starting with select adult doses this Monday. The strategy banks on Ozempic’s blockbuster brand recognition to lift sales and help Novo regain market share from rival Eli Lilly as competition intensifies in diabetes care.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Novo Nordisk’s partial phase out of a key insulin product in India may create a supply gap that competitors are ready to fill. Eris Pharma and its contract manufacturing partner Biocon Biologics could benefit as demand shifts and procurement patterns adjust. The move could trigger pricing and market share changes across India’s insulin landscape, with near-term opportunities for local players.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
